Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Birju Patel

Child & Adolescent Psychiatry Kenilworth, IL Medical Doctor

NPI 1699018317 CMS profile 2255972

444 Green Bay Rd, Kenilworth, IL 60043

Open in the dashboard

General payments

$4,753

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Birju Patel of Kenilworth, IL is reported in the CMS Open Payments database as having received $4,753 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,193 67
2024 General $1,842 92
2023 General $1,146 49
2022 General $155 8
2020 General $109 5
2019 General $308 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Birju Patel
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Birju Patel were reported at $1,193. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Birju Patel Child & Adolescent Psychiatry median Middle half National median
2019 $308 $129 $42–$419 $163
2020 $109 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $155 $124 $40–$382 $149
2023 $1,146 $130 $45–$420 $160
2024 $1,842 $141 $42–$490 $164
2025 $1,193 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $811 36 payments
  2. Tris Pharma Inc $570 20 payments
  3. AbbVie, Inc. $551 38 payments
  4. Corium, Inc. $492 21 payments
  5. Neos Therapeutics, LP $363 20 payments
  6. Otsuka America Pharmaceutical, Inc. $321 16 payments
  7. E.R. Squibb & Sons, L.L.C. $289 9 payments
  8. Lundbeck LLC $226 12 payments
  9. Ironshore Pharmaceuticals Inc. $202 13 payments
  10. Janssen Pharmaceuticals, Inc $160 7 payments
  11. Other $767 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,753 229 payments
Products named General payments · program years 2019–2025
  1. Qelbree $683 29 payments
  2. Azstarys $492 21 payments
  3. VRAYLAR $416 25 payments
  4. Dyanavel XR Adhd $306 15 payments
  5. REXULTI Psychiatry $301 15 payments
  6. Dyanavel XR Adhd $242 2 payments
  7. REXULTI Psychiatry $226 12 payments
  8. JORNAY PM $202 13 payments
  9. Adzenys XR-ODT $199 11 payments
  10. COTEMPLA XR-ODT $165 9 payments
  11. Other $1,627 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record